Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

fosaprepitant

Known as: Fosaprepitantum 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Introduction Fosaprepitant, an intravenous (IV) aprepitant prodrug for chemotherapy-induced nausea and vomiting prophylaxis, is… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2016
2016
This phase III trial demonstrated that adding a single dose of fosaprepitant to a 5-HT3 receptor antagonist and corticosteroid in… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
Highly Cited
2016
Highly Cited
2016
BACKGROUND We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly… Expand
  • figure 1
  • figure 2
  • table 1
2015
2015
INTRODUCTION The oral neurokinin-1 antagonist aprepitant is recommended in several guidelines for preventing chemotherapy-induced… Expand
2015
2015
BACKGROUND Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary… Expand
  • table I
  • table II
  • table III
Highly Cited
2013
Highly Cited
2013
Background We evaluated the efficacy and safety of single-dose fosaprepitant in combination with intravenous granisetron and… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Highly Cited
2011
Highly Cited
2011
PURPOSE Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves… Expand
2011
2011
Aprepitant or its prodrug fosaprepitant, in combination with a corticosteroid and a 5‐HT3 receptor antagonist, are used to… Expand
Highly Cited
2007
Highly Cited
2007
Fosaprepitant is an intravenous formulation of aprepitant, an oral NK1 antagonist used to prevent chemotherapy‐induced nausea and… Expand
Review
2007
Review
2007
  • R. Navari
  • Expert opinion on investigational drugs
  • 2007
  • Corpus ID: 21437603
Chemotherapy-induced nausea and vomiting (CINV) is a distressing and common adverse event associated with cancer treatment… Expand